Bio3 Research's business strategy is aimed at developing its innovative projects originated  in house or at Research  Institutions, with which has entered into alliances, up to the Phase I/IIA stage.
Thanks to   its large network in the biopharmaceutical field, Bio3 Research develops marketing and Licensing-out strategies to maximize the projects business potential.

Bio3 Research has recently been granted from USPTO the US patent # 10/471,641 which claims the use of HMGB1 inhibitors and antagonists for the treatment of Cardiovascular Disorders…

You may also notice that we have a new website. This site was built by a company based in the UK called Sinful Design. They can be found at;

www.sinfuldesign.com